Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
13th Nov 2006, 18:39 GMT
Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data related news:
- Amgen arthritis drug shows sustained safety and efficacy — Pharmaceutical Business Review Latest News
- Genentech to Buy Tanox for $919M and Amgen and Wyeth's ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy — Financial News USA (OTC: FNWU)
- Long-Term Data Shows No Increase In Cancer Cases From Biologic Therapy — Health News from Medical News Today
- Impact Of Rheumatoid Arthritis Goes Beyond Signs And Symptoms, Delay In Treatment May Impact Long-Term Employment — Health News from Medical News Today
- Data Shows ENBREL Provides Sustained Clinical Improvements For People With Ankylosing Spondylitis For Up To Three Years — Health News from Medical News Today
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years — EurekAlert! - Medicine and Health
- Mayo Clinic information about accelerated aging among people with rheumatoid arthritis — EurekAlert! - Breaking News
- Accelerated Aging Among People With Rheumatoid Arthritis — ScienceDaily Headlines: Health & Medicine
- Adalimumab Proves Effective For Children With Juvenile Rheumatoid Arthritis — Health News from Medical News Today
- Actemra™ Has A Major Impact On Improving Remission Rates In Rheumatoid Arthritis - 3 Studies From The Japanese Phase III Trial Programme — Health News from Medical News Today
Latest news from EurekAlert! - Medicine and Health:
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
- UCSD computer scientist wins Young Investigator Award, research on snake venom proteins highlighted
- Why do insects like to eat some plants more than others?
- Opposites do not attract
- Wild gorillas carriers of an SIV virus close to the AIDS virus
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
- Pourquié lab identifies genes involved in formation of vertebral precursors
- Artificial cornea offers better results for infants, some blind patients
- Healthier kids just the click of a remote away
- Adolescents, risks and the pitfalls of rationality